

UGANDA Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

| | | | | | |
|---|-------------|-------------|-------------|-------------|--------------------|
| 1. Country: Uganda | | | | | |
| 2. Grant number: 1720-UGA-13b-X / 17-UGA-08b-Y | | | | | |
| 3. Date of Decision Letter: 26 September 2016 | | | | | |
| 4. Date of the Partnership Framework Agreement: 28 June 2013 | | | | | |
| 5. Programme title: New Vaccine Support (NVS), Rotavirus Routine | | | | | |
| 6. Vaccine type: Rotavirus | | | | | |
| 7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule | | | | | |
| 8. Programme duration¹: 2017 - 2020 | | | | | |
| 9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable) | | | | | |
| | 2017 | 2018 | 2019 | 2020 | Total ² |
| Programme Budget (US\$) | \$6,560,500 | \$7,798,500 | \$7,663,500 | \$8,081,500 | \$30,104,000 |
| 10. Vaccine introduction grant (in US\$): 1,435,644. Payable up to six months before vaccine introduction. | | | | | |
| 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ³ | | | | | |
| Type of supplies to be purchased with Gavi funds in each year | | | | | 2017 |
| Number of Rotavirus vaccines doses | | | | | 2,917,500 |
| Annual Amounts (US\$) | | | | | US\$6,560,500 |
| 12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF. | | | | | |
| 13. Self-procurement: not applicable | | | | | |

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

14. Co-financing obligations: Reference code: 1720-UGA-13b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

| Type of supplies to be purchased with Country funds in each year | 2017 | 2018 | 2019 | 2020 |
|--|-------------|-------------|-------------|-------------|
| Number of vaccine doses | 285,000 | 339,000 | 333,000 | 351,000 |
| Value of vaccine doses (US\$) | US\$623,906 | US\$741,673 | US\$728,815 | US\$768,558 |
| Total co-financing payments (US\$) (including freight) | US\$640,500 | US\$761,500 | US\$748,500 | US\$789,000 |

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable

| Reports and other information | Due dates |
|---|-------------------------------|
| To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | May |
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Secretariat |

17. Financial clarifications: Country shall provide the following clarifications to Gavi*:
N/A

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: N/A

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

26 September 2016